Cryoprobe Biopsy Improves Diagnostic Yield in Transbronchial Biopsy

Bronchoscopic biopsy is a standard procedure for diagnosing pulmonary lesions. But the conventional method using forceps can result in small specimen sizes and poor specimen quality due to crush artifact, which may compromise diagnostic accuracy.^1-3 This limitation necessitates alternative approaches to improve tissue acquisition.

Cryobiopsy Localizes Freezing to Retrieve Intact Specimens and Improve Yield

Cryobiopsy replaces the mechanical shearing of conventional forceps with localized freezing to extract larger pulmonary specimens. Pulmonary lesions present a diagnostic challenge where early identification dictates treatment planning. Conventional transbronchial biopsy using forceps often returns inconclusive results because the tool crushes the tissue. These delays force clinicians into repeat procedures or surgical biopsies. Cryoprobe technology solves this by adhering to the tissue via freezing.

The FROSTBITE-2 Randomized Clinical Trial, published in JAMA in 2026, investigated the efficacy of cryobiopsy versus forceps for bronchoscopic lung biopsy. The trial demonstrated that cryoprobe use localizes freezing at the probe tip, which enables the retrieval of larger, more intact biopsy specimens.¹ This mechanism directly addresses the limitations observed with forceps, where crush artifact frequently degrades specimen quality.¹ The trial randomized a diverse patient population with suspected malignancies and interstitial lung diseases to receive either cryobiopsy or conventional forceps biopsy. The primary outcome measured diagnostic yield, defined as the proportion of biopsies providing a definitive diagnosis.

But this trial leaves practical questions unanswered. The study design randomized patients in highly controlled academic centers with expert operators. It does not establish whether community pulmonologists will achieve the same diagnostic yield. The primary endpoint measured the proportion of biopsies providing a definitive diagnosis, but it did not track long-term patient survival or the downstream cost savings of avoiding surgical biopsy. The population also excluded patients with severe bleeding risks.

For respiratory physicians, this shifts the initial approach to complex pulmonary lesions. Clinicians should consider cryobiopsy as a first-line option for interstitial lung diseases where tissue architecture dictates the diagnosis. You must prepare patients for a slightly longer procedure time while explaining that the technique reduces their risk of needing a surgical biopsy. The need for a method that consistently yields higher-quality tissue samples is met by this approach.

Tissue Freezing Preserves Cellular Architecture Across Diverse Anatomical Locations

The primary benefit of cryoprobe technology is its ability to preserve tissue architecture across both peripheral nodules and mediastinal lymph nodes. By freezing the tissue, the cryoprobe minimizes mechanical distortion that is common with forceps, leading to specimens that are more amenable to pathological examination. This reduction in crush artifact and increase in specimen size directly contribute to a higher diagnostic yield, potentially reducing the need for repeat procedures and accelerating patient management.^1-3

A 2025 study in the Journal of Visualized Experiments examined ultrafine bronchoscopy combined with frozen lung biopsy for peripheral pulmonary nodules. This study concluded that cryoprobe use localizes freezing at the probe tip, facilitating the retrieval of larger, more intact biopsy specimens compared to conventional forceps.² A prospective observational study, published in Annals of Medicine in 2025, compared sequential cryoprobe and biopsy forceps in endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal and hilar lesions. This study also reported that cryoprobe use localizes freezing at the probe tip, enabling the retrieval of larger, more intact biopsy specimens.³

Neither study provides a definitive mandate to abandon forceps entirely. The peripheral nodule study evaluated a highly specific combination of ultrafine bronchoscopy and cryobiopsy. It lacks a direct comparison to robotic-assisted bronchoscopy. The endobronchial ultrasound study used a sequential observational design rather than randomizing patients. Extracting tissue from the same lesion with both tools introduces sequence bias, as the first pass alters the tissue bed for the second pass. These designs do not establish superiority in all clinical scenarios.

The mechanism involves rapid freezing of the tissue at the probe tip, creating a strong adhesion between the tissue and the probe. When the probe is withdrawn, it pulls a cohesive piece of tissue compared to the shearing action of forceps. This gentle extraction method maintains cellular integrity for accurate histopathological diagnosis. For pathologists, receiving a well-preserved specimen means clearer margins and better cellular detail. Clinicians navigating peripheral airways or staging mediastinal nodes should integrate cryoprobes when rapid on-site evaluation indicates insufficient cellularity from initial forceps passes.

Procedural Learning Curves and Bleeding Risks Limit Universal Adoption

Cryobiopsy requires specialized equipment and advanced operator training that restrict its immediate rollout in all clinical settings. The technique demands precise timing during the freezing cycle and rapid extraction of the bronchoscope. Operators must manage the airway differently than they do during conventional forceps biopsy. This learning curve dictates how quickly a department can transition to cryoprobe technology.

The FROSTBITE-2 trial and the observational studies focus heavily on diagnostic yield while treating safety as a secondary endpoint. These trials establish that cryobiopsy retrieves larger specimens, but pulling larger pieces of highly vascularized lung tissue inherently alters the risk profile. Although the 2025 and 2026 studies report a favorable safety profile, potential risks such as bleeding or pneumothorax still exist and require careful management. The safety profile observed reinforces the viability of cryobiopsy, but only under strict procedural guidelines.

Current data fail to define the exact learning curve for safe implementation. The published trials exclude patients with severe pulmonary hypertension or uncorrectable coagulopathies. They do not establish a standardized training protocol for fellows or transitioning attendings. The safety metrics rely on procedures performed by high-volume interventional pulmonologists. This means the complication rates likely underestimate what would occur in a low-volume community practice.

Institutions adopting cryobiopsy must implement rigorous training protocols before offering the procedure. Pulmonologists should use prophylactic endobronchial blockers during early cases to manage potential bleeding. You must counsel patients that while the technique improves the chance of a definitive diagnosis, it carries specific risks of pneumothorax that might require chest tube placement. Start with central, less vascular lesions before advancing to peripheral nodules.